| Year |
Citation |
Score |
| 2024 |
Shrestha N, Dee MJ, Chaturvedi P, Leclerc GM, Mathyer M, Dufour C, Arthur L, Becker-Hapak M, Foster M, McClain E, Pena NV, Kage K, Zhu X, George V, Liu B, ... ... Fehniger TA, et al. A "Prime and Expand" strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapy. Cancer Immunology, Immunotherapy : Cii. 73: 179. PMID 38960949 DOI: 10.1007/s00262-024-03765-8 |
0.35 |
|
| 2024 |
Foltz JA, Tran J, Wong P, Fan C, Schmidt E, Fisk B, Becker-Hapak M, Russler-Germain DA, Johnson J, Marin ND, Cubitt CC, Pence P, Rueve J, Pureti S, Hwang K, ... ... Fehniger TA, et al. Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulation. Science Immunology. 9: eadk4893. PMID 38941480 DOI: 10.1126/sciimmunol.adk4893 |
0.417 |
|
| 2024 |
Cubitt CC, Wong P, Dorando HK, Foltz JA, Tran J, Marsala L, Marin ND, Foster M, Schappe T, Fatima H, Becker-Hapak M, Zhou AY, Hwang K, Jacobs MT, Russler-Germain DA, ... ... Fehniger TA, et al. Induced CD8α identifies human NK cells with enhanced proliferative fitness and modulates NK cell activation. The Journal of Clinical Investigation. PMID 38805302 DOI: 10.1172/JCI173602 |
0.437 |
|
| 2024 |
Marin ND, Becker-Hapak M, Song WM, Alayo QA, Marsala L, Sonnek N, Berrien-Elliott MM, Foster M, Foltz JA, Tran J, Wong P, Cubitt CC, Pence P, Hwang K, Zhou AY, ... ... Fehniger TA, et al. Memory-like differentiation enhances NK cell responses against colorectal cancer. Oncoimmunology. 13: 2348254. PMID 38737793 DOI: 10.1080/2162402X.2024.2348254 |
0.434 |
|
| 2023 |
Pizzato HA, Alonso-Guallart P, Woods J, Connelly JP, Fehniger TA, Atkinson JP, Pruett-Miller SM, Monsma FJ, Bhattacharya D. Engineering human pluripotent stem cell lines to evade xenogeneic transplantation barriers. Stem Cell Reports. PMID 38215755 DOI: 10.1016/j.stemcr.2023.12.003 |
0.375 |
|
| 2023 |
Ghobadi A, Foley NC, Cohen J, Rettig MP, Cashen AF, Gehrs LN, Christ S, Street E, Wallace N, Ritchey JK, Mehta-Shah N, Westervelt P, Fehniger TA, Kahl BS, Bartlett NL, et al. Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma. Blood Advances. PMID 37871306 DOI: 10.1182/bloodadvances.2023011130 |
0.315 |
|
| 2023 |
Jacobs MT, Wong P, Zhou AY, Becker-Hapak M, Marin ND, Marsala L, Foster M, Foltz JA, Cubitt CC, Tran J, Russler-Germain DA, Neal C, Kersting-Schadek S, Chang L, Schappe T, ... ... Fehniger TA, et al. Memory-like differentiation, tumor targeting monoclonal antibodies, and chimeric antigen receptors enhance natural killer cell responses to head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37556118 DOI: 10.1158/1078-0432.CCR-23-0156 |
0.332 |
|
| 2023 |
Pizzato HA, Alonso-Guallart P, Woods J, Johannesson B, Connelly JP, Fehniger TA, Atkinson JP, Pruett-Miller SM, Monsma FJ, Bhattacharya D. Engineering Human Pluripotent Stem Cell Lines to Evade Xenogeneic Transplantation Barriers. Biorxiv : the Preprint Server For Biology. PMID 37425790 DOI: 10.1101/2023.06.27.546594 |
0.337 |
|
| 2023 |
O'Neal J, Cooper ML, Ritchey JK, Gladney SW, Niswonger J, Gonzalez LS, Street E, Haas GJ, Carter AJ, Amayta PN, Gao F, Lee BH, Choi D, Berrien-Elliott MM, Zhou AY, ... Fehniger TA, et al. Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7hyFc. Blood Advances. PMID 37399471 DOI: 10.1182/bloodadvances.2023010032 |
0.303 |
|
| 2023 |
Wong P, Foltz JA, Chang L, Neal CC, Yao T, Cubitt CC, Tran J, Kersting-Schadek S, Palakurty SX, Jaeger N, Russler-Germain DA, Marin ND, Gang M, Wagner JA, Zhou AY, ... ... Fehniger TA, et al. T-BET and EOMES sustain mature human NK cell identity and anti-tumor function. The Journal of Clinical Investigation. PMID 37279078 DOI: 10.1172/JCI162530 |
0.337 |
|
| 2022 |
Al-Kadhimi Z, Callahan M, Fehniger T, Cole KE, Vose J, Hinrichs S. Enrichment of innate immune cells from PBMC followed by triple cytokine activation for adoptive immunotherapy. International Immunopharmacology. 113: 109387. PMID 36461582 DOI: 10.1016/j.intimp.2022.109387 |
0.414 |
|
| 2022 |
Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood. PMID 36416736 DOI: 10.1182/blood.2022016200 |
0.397 |
|
| 2022 |
Berrien-Elliott MM, Foltz JA, Russler-Germain DA, Neal CC, Tran J, Gang M, Wong P, Fisk B, Cubitt CC, Marin ND, Zhou AY, Jacobs MT, Foster M, Schappe T, McClain E, ... ... Fehniger TA, et al. Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Science Translational Medicine. 14: eabm1375. PMID 35196021 DOI: 10.1126/scitranslmed.abm1375 |
0.477 |
|
| 2021 |
Bednarski JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, Becker-Hapak M, Neal CC, Foster M, Schappe T, McClain E, Pence P, Desai S, Kersting-Schadek S, Wong P, Russler-Germain DA, Fisk B, ... ... Fehniger TA, et al. Donor Memory-like NK cells Persist and Induce Remissions in Pediatric Patients with Relapsed AML after Transplant. Blood. PMID 34871371 DOI: 10.1182/blood.2021013972 |
0.442 |
|
| 2021 |
Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs MT, Wong P, Foster M, McClain E, Desai S, Pence P, Cooley S, Brunstein CG, Gao F, Abboud CN, Uy GL, Westervelt P, ... ... Fehniger TA, et al. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood. PMID 34797911 DOI: 10.1182/blood.2021011532 |
0.368 |
|
| 2021 |
Ward J, Berrien-Elliott MM, Gomez F, Luo J, Becker-Hapak M, Cashen AF, Wagner-Johnston ND, Maddocks K, Mosior M, Foster M, Krysiak K, Schmidt A, Skidmore ZL, Desai S, Watkins MP, ... ... Fehniger TA, et al. Phase I/Dose Expansion Trial of Brentuximab vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Blood. PMID 34780623 DOI: 10.1182/blood.2021011894 |
0.301 |
|
| 2021 |
Becker-Hapak MK, Shrestha N, McClain E, Dee MJ, Chaturvedi P, Leclerc GM, Marsala LI, Foster M, Schappe T, Tran J, Desai S, Neal CC, Pence P, Wong P, Wagner JA, ... ... Fehniger TA, et al. A fusion protein complex that combines IL12, IL15, and IL18 signaling to induce memory-like NK cells for cancer immunotherapy. Cancer Immunology Research. PMID 34244297 DOI: 10.1158/2326-6066.CIR-20-1002 |
0.36 |
|
| 2021 |
Marin ND, Krasnick BA, Becker-Hapak M, Conant L, Goedegebuure SP, Berrien-Elliott MM, Robbins KJ, Foltz JA, Foster M, Wong P, Cubitt CC, Tran J, Wetzel CB, Jacobs M, Zhou A, ... ... Fehniger TA, et al. Memory-like differentiation enhances NK cell responses to melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34187852 DOI: 10.1158/1078-0432.CCR-21-0851 |
0.375 |
|
| 2021 |
Mah-Som AY, Keppel MP, Tobin JM, Kolicheski A, Saucier N, Sexl V, French AR, Wagner JA, Fehniger TA, Cooper MA. Reliance on Cox10 and oxidative metabolism for antigen-specific NK cell expansion. Cell Reports. 35: 109209. PMID 34077722 DOI: 10.1016/j.celrep.2021.109209 |
0.354 |
|
| 2021 |
Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak MK, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, ... ... Fehniger TA, et al. Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33986022 DOI: 10.1158/1078-0432.CCR-21-0164 |
0.368 |
|
| 2021 |
Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak MK, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, ... ... Fehniger TA, et al. Phase 1 trial of N-803, an IL-15 receptor agonist, with rituximab in patients with indolent non-Hodgkin lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33832946 DOI: 10.1158/1078-0432.CCR-20-4575 |
0.352 |
|
| 2021 |
Wong P, Wagner JA, Berrien-Elliott MM, Schappe T, Fehniger TA. Flow cytometry-based murine NK cell cytotoxicity assay. Star Protocols. 2: 100262. PMID 33490978 DOI: 10.1016/j.xpro.2020.100262 |
0.364 |
|
| 2021 |
Zhou A, Rettig M, Foltz J, Luo J, Butt O, Avvaru C, Katumba R, Kim A, Dunn G, Abraham C, Yang SH, Fan J, Lee BH, Le N, Ansstas G, ... ... Fehniger T, et al. 396 NT-I7, a long-acting interleukin-7, promotes expansion of CD8 T cells and NK cells and immune activation in patients with newly diagnosed high-grade gliomas after chemoradiation Journal For Immunotherapy of Cancer. 9: A428-A428. DOI: 10.1136/jitc-2021-sitc2021.396 |
0.344 |
|
| 2021 |
Sullivan R, Mathyer M, Govero J, Dean J, Martens A, Zhou Y, Darwech M, Tumala B, Vessoni A, Hamil A, Leedom T, Johnson C, Berrien-Elliot M, Foster M, Becker-Hapak M, ... ... Fehniger T, et al. 188 Development of WU-NK-101, a feeder cell-free expanded allogeneic memory NK cell product with potent anti-tumor activity Journal For Immunotherapy of Cancer. 9: A200-A200. DOI: 10.1136/jitc-2021-sitc2021.188 |
0.409 |
|
| 2020 |
Gang M, Wong P, Berrien-Elliott MM, Fehniger TA. Memory-like natural killer cells for cancer immunotherapy. Seminars in Hematology. 57: 185-193. PMID 33256911 DOI: 10.1053/j.seminhematol.2020.11.003 |
0.318 |
|
| 2020 |
Shea L, Watkins MP, Wan F, Cashen A, Wagner-Johnston N, Jacoby M, Abboud C, Dipersio J, Hurd D, Jaglowski S, Bartlett NL, Fehniger T. A pilot study of lenalidomide maintenance therapy after autologous transplantation in relapsed or refractory classical Hodgkin lymphoma. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 32829079 DOI: 10.1016/J.Bbmt.2020.08.017 |
0.337 |
|
| 2020 |
Berrien-Elliott MM, Cashen AF, Cubitt CC, Neal CC, Wong P, Wagner JA, Foster M, Schappe T, Desai S, McClain E, Becker-Hapak M, Foltz JA, Cooper ML, Jaeger N, Nonavinkere Srivatsan S, ... ... Fehniger TA, et al. Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia. Cancer Discovery. PMID 32826231 DOI: 10.1158/2159-8290.Cd-20-0312 |
0.517 |
|
| 2020 |
Gang M, Marin ND, Wong P, Neal CC, Marsala L, Foster M, Schappe T, Meng W, Tran J, Schaettler M, Davila ML, Gao F, Cashen AF, Bartlett NL, Mehta-Shah N, ... ... Fehniger TA, et al. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas. Blood. PMID 32614951 DOI: 10.1182/Blood.2020006619 |
0.509 |
|
| 2020 |
Gunesch JT, Dixon AL, Ebrahim TA, Berrien-Elliott M, Tatineni S, Kumar T, Hegewisch-Solloa E, Fehniger TA, Mace EM. CD56 regulates human NK cell cytotoxicity through Pyk2. Elife. 9. PMID 32510326 DOI: 10.7554/Elife.57346 |
0.414 |
|
| 2020 |
Wagner JA, Wong P, Schappe T, Berrien-Elliott MM, Cubitt C, Jaeger N, Lee M, Keppel CR, Marin ND, Foltz JA, Marsala L, Neal CC, Sullivan RP, Schneider SE, Keppel MP, ... ... Fehniger TA, et al. Stage-Specific Requirement for Eomes in Mature NK Cell Homeostasis and Cytotoxicity. Cell Reports. 31: 107720. PMID 32492428 DOI: 10.1016/J.Celrep.2020.107720 |
0.762 |
|
| 2020 |
Oza A, Rettig MP, Powell P, O'Brien K, Clifford DB, Ritchey J, Gehrs L, Hollaway J, Major E, Fehniger TA, Miller CA, Soon-Shiong P, Rock A, DiPersio JF. Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient. Blood Advances. 4: 2387-2391. PMID 32484854 DOI: 10.1182/Bloodadvances.2019000664 |
0.343 |
|
| 2020 |
Dege C, Fegan KH, Creamer JP, Berrien-Elliott MM, Luff SA, Kim D, Wagner JA, Kingsley PD, McGrath KE, Fehniger TA, Palis J, Sturgeon CM. Potently Cytotoxic Natural Killer Cells Initially Emerge from Erythro-Myeloid Progenitors during Mammalian Development. Developmental Cell. PMID 32197069 DOI: 10.1016/J.Devcel.2020.02.016 |
0.5 |
|
| 2020 |
Mack MR, Brestoff JR, Berrien-Elliott MM, Trier AM, Yang TB, McCullen M, Collins PL, Niu H, Bodet ND, Wagner JA, Park E, Xu AZ, Wang F, Chibnall R, Council ML, ... ... Fehniger TA, et al. Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. Science Translational Medicine. 12. PMID 32102931 DOI: 10.1126/Scitranslmed.Aay1005 |
0.454 |
|
| 2020 |
Weisdorf D, Cooley S, Wang T, Trachtenberg E, Vierra-Green C, Spellman S, Sees JA, Spahn A, Vogel J, Fehniger TA, Woolfrey AE, Devine SM, Ross M, Waller EK, Sobecks RM, et al. KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation. Blood Advances. 4: 740-754. PMID 32092137 DOI: 10.1182/Bloodadvances.2019001053 |
0.377 |
|
| 2020 |
Gunesch JT, Dixon AL, Ebrahim TA, Berrien-Elliott MM, Tatineni S, Kumar T, Hegewisch-Solloa E, Fehniger TA, Mace EM. Author response: CD56 regulates human NK cell cytotoxicity through Pyk2 Elife. DOI: 10.7554/Elife.57346.Sa2 |
0.409 |
|
| 2020 |
Kerbauy L, Marin N, Kaplan M, Banerjee P, Berrien-Elliott M, Becker-Hapak M, Basar R, Foster M, Melo LG, Neal C, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, ... ... Fehniger T, et al. 531 AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies Journal For Immunotherapy of Cancer. 8: A567-A567. DOI: 10.1136/jitc-2020-sitc2020.0531 |
0.444 |
|
| 2020 |
Mack MR, Brestoff JR, Berrien-Elliott MM, Yang TB, Trier AM, Collins PL, Niu H, Bodet ND, Wagner JA, Park E, Xu AZ, Wang F, McCullen M, Chibnall R, Margolis DJ, ... ... Fehniger TA, et al. 852 Natural killer cell deficiency reveals a novel immunotherapy strategy for atopic dermatitis Journal of Investigative Dermatology. 140. DOI: 10.1016/J.Jid.2020.03.868 |
0.425 |
|
| 2019 |
Berrien-Elliott MM, Sun Y, Neal C, Ireland A, Trissal MC, Sullivan RP, Wagner JA, Leong JW, Wong P, Mah-Som AY, Wong TN, Schappe T, Keppel CR, Cortez VS, Stamatiades EG, ... ... Fehniger TA, et al. MicroRNA-142 Is Critical for the Homeostasis and Function of Type 1 Innate Lymphoid Cells. Immunity. PMID 31402259 DOI: 10.1016/J.Immuni.2019.06.016 |
0.341 |
|
| 2019 |
Tschan-Plessl A, Ask EH, Gjerdingen TJ, Saetersmoen M, Hoel HJ, Wiiger MT, Olweus J, Wahlin BE, Horowitz A, Fehniger TA, Holte H, Kolstad A, Malmberg K. System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival Blood. 134: 2897-2897. DOI: 10.1182/Blood-2019-131359 |
0.345 |
|
| 2019 |
Dege C, Fegan KH, Creamer JP, Berrien-Elliott MM, Luff SA, Wagner JA, Kingsley PD, McGrath KE, Fehniger TA, Palis J, Sturgeon CM. Potently Cytotoxic Natural Killer Cell Potential Initially Emerges from Erythro-Myeloid Progenitors during Mammalian Development Blood. 134: 2464-2464. DOI: 10.1182/Blood-2019-130347 |
0.513 |
|
| 2019 |
Berrien-Elliott MM, Pamela W, Neal C, Wagner JA, Becker-Hapak M, Schappe T, Cooper ML, Mace EM, Fehniger TA. Primary Human NK Cell Gene-Editing Reveals a Critical Role for NKG2A in Cytokine-Induced Memory-like NK Cell Responses Blood. 134: 3237-3237. DOI: 10.1182/Blood-2019-129162 |
0.455 |
|
| 2019 |
Berrien-Elliott MM, Gang M, Agudelo NMM, Marsala LM, Foster M, Neal C, Pamela W, Meng WM, Schaettler MM, Schappe T, Fehniger TA. Chimeric Antigen Receptor Modified Memory-like (CAR-ML) NK Cells Exhibit Potent Responses to NK-Resistant Tumors Blood. 134: 869-869. DOI: 10.1182/Blood-2019-127546 |
0.386 |
|
| 2019 |
Bednarski JJ, Zimmerman C, Cashen AF, Desai S, Foster M, Schappe T, McClain E, Becker-Hapak M, Berrien-Elliott MM, Fehniger TA. Adoptively Transferred Donor-Derived Cytokine Induced Memory-like NK Cells Persist and Induce Remission in Pediatric Patient with Relapsed Acute Myeloid Leukemia after Hematopoietic Cell Transplantation Blood. 134: 3307-3307. DOI: 10.1182/Blood-2019-126982 |
0.529 |
|
| 2019 |
Foltz JA, Berrien-Elliott MM, Neal C, Foster M, McClain E, Schappe T, Desai S, Becker-Hapak M, Cashen AF, Fehniger TA. Cytokine-Induced Memory-like (ML) NK Cells Persist for > 2 Months Following Adoptive Transfer into Leukemia Patients with a MHC-Compatible Hematopoietic Cell Transplant (HCT) Blood. 134: 1954-1954. DOI: 10.1182/Blood-2019-126004 |
0.46 |
|
| 2019 |
Marin N, Becker-Hapak M, Koch J, Berrien-Elliott MM, Foster M, Neal C, McClain E, Desai S, Wagner JA, Schappe T, Marsala L, Wong P, Treder M, Fehniger TA. Abstract 1546: The CD30/CD16A bispecific innate immune cell engager AFM13 elicits heterogeneous single-cell NK cell responses and effectively triggers memory-like (ML) NK cells Immunology. DOI: 10.1158/1538-7445.Sabcs18-1546 |
0.478 |
|
| 2019 |
Sturgeon C, Dege C, Fegan K, Creamer JP, Berrien-Elliot M, Luff S, Kim D, Wagner J, Kingsley P, Fehniger T, McGrath K, Palis J, Sturgeon C. ONTOGENY IS A CRITICAL DETERMINANT OF NATURAL KILLER CELL POTENTIAL AND FUNCTION Experimental Hematology. 76: S87. DOI: 10.1016/J.Exphem.2019.06.440 |
0.497 |
|
| 2019 |
Gomez F, Skidmore Z, Schmidt A, Rodrigues-Martins F, Krysiak K, Ramirez C, Mosior M, Duncavage E, Triska G, Trani L, Bartlett N, Cashen A, Mehta-Shah N, Kahl B, Kreisel F, ... ... Fehniger T, et al. 23. Ultra-deep sequencing of classical Hodgkin lymphoma (cHL) reveals novel somatic mutations and exemplifies the utility of deep sequencing in the characterization of rare malignant cells Cancer Genetics and Cytogenetics. DOI: 10.1016/J.Cancergen.2019.04.029 |
0.306 |
|
| 2018 |
Orange JS, Mace EM, French AR, Yokoyama WM, Fehniger TA, Cooper MA. Comment on: Evidence of innate lymphoid cell redundancy in humans. Nature Immunology. 19: 788-789. PMID 30026477 DOI: 10.1038/S41590-018-0164-5 |
0.387 |
|
| 2018 |
Fehniger TA, Miller JS, Stuart RK, Cooley S, Salhotra A, Curtsinger J, Westervelt P, DiPersio JF, Hillman TM, Silver N, Szarek M, Gorelik L, Lowdell MW, Rowinsky E. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 29597002 DOI: 10.1016/J.Bbmt.2018.03.019 |
0.512 |
|
| 2018 |
Bansal D, Vij K, Chang GS, Miller CA, DiPersio JF, Vij R, Heath SE, Westervelt P, Welch JS, Fehniger TA. Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T cell infiltrate in the bone marrow. Haematologica. PMID 29567774 DOI: 10.3324/Haematol.2017.184168 |
0.337 |
|
| 2018 |
Romee R, Cooley S, Berrien-Elliott MM, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Ustun C, DeFor TE, Vivek S, Peck L, DiPersio JF, Cashen AF, Kyllo R, ... ... Fehniger TA, et al. First-in-human Phase 1 Clinical Study of the IL-15 Superagonist Complex ALT-803 to Treat Relapse after Transplantation. Blood. PMID 29463563 DOI: 10.1182/Blood-2017-12-823757 |
0.474 |
|
| 2018 |
Dege C, McGrath KE, Berrien-Elliott MM, Fegan KH, Wagner JA, Fehniger TA, Palis J, Sturgeon C. Ontogeny As a Critical Determinant of Natural Killer Cell Potential and Function Blood. 132: 1271-1271. DOI: 10.1182/Blood-2018-99-119812 |
0.512 |
|
| 2018 |
Mehta-Shah N, Riedell PA, Bartlett NL, Cashen AF, Kahl BS, Fehniger TA, Moreno C, Carson KR. Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive Lymphomas Including AITL and DLBCL: Phase I Results Blood. 132: 2929-2929. DOI: 10.1182/Blood-2018-99-113611 |
0.308 |
|
| 2018 |
Berrien-Elliott MM, Wagner JA, Cashen AF, Fehniger TA. Memory-Like Natural Killer Cells Blood. 132. DOI: 10.1182/Blood-2018-99-109537 |
0.495 |
|
| 2018 |
Fehniger TA, Hess BT, Bachanova V, Becker-Hapak M, McClain E, Berrien-Elliott M, Wagner J, Bartlett NL, Kahl B, Mehta-Shah N, Cashen AF, Gao F, Conradi K, Rock AD, Jeng EK, et al. Abstract CT146: First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL) Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct146 |
0.394 |
|
| 2018 |
Berrien-Elliott MM, Wagner JA, Romee R, Becker-Hapak M, Schappe T, Neal C, McClain E, DiPersio J, Westervelt P, Cashen AF, Fehniger TA. Abstract 5704: Mass cytometry identifies the expansion, persistence, and immune checkpoints of adoptively transferred memory-like NK cells in patients with leukemia Immunology. DOI: 10.1158/1538-7445.Am2018-5704 |
0.389 |
|
| 2018 |
Abboud R, Slade M, Keller J, Trinkaus K, Abboud C, DiPersio JF, Ghobadi A, Fehniger T, Romee R. T-Cell Replete Peripheral Blood Haploidentical Donor Transplant is Frequently Associated with Cytokine Release Syndrome Which Responds to IL-6 Inhibition—Updated Outcomes Data with Longer Follow-Up Biology of Blood and Marrow Transplantation. 24. DOI: 10.1016/J.Bbmt.2017.12.363 |
0.364 |
|
| 2017 |
Cooper MA, Fehniger TA, Colonna M. Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination? Vaccination Strategies Based on NK Cell and ILC Memory. Cold Spring Harbor Perspectives in Biology. PMID 29254976 DOI: 10.1101/Cshperspect.A029512 |
0.374 |
|
| 2017 |
Mah AY, Rashidi A, Keppel MP, Saucier N, Moore EK, Alinger JB, Tripathy SK, Agarwal SK, Jeng EK, Wong HC, Miller JS, Fehniger TA, Mace EM, French AR, Cooper MA. Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control. Jci Insight. 2. PMID 29212951 DOI: 10.1172/Jci.Insight.95128 |
0.454 |
|
| 2017 |
Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, Thye LS, Anderson DM, Krysiak K, Ramirez C, Qi J, Siegel BA, Griffith M, Griffith OL, Gomez F, ... Fehniger TA, et al. Single-Agent Ibrutinib in Relapsed or Refractory Follicular Lymphoma: A Phase 2 Consortium Trial. Blood. PMID 29074501 DOI: 10.1182/Blood-2017-09-804641 |
0.34 |
|
| 2017 |
Cossarizza A, Chang HD, Radbruch A, Andrä I, Annunziato F, Bacher P, Barnaba V, Battistini L, Bauer WM, Baumgart S, Becher B, Beisker W, Berek C, Blanco A, Borsellino G, ... ... Fehniger TA, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies. European Journal of Immunology. 47: 1584-1797. PMID 29023707 DOI: 10.1002/Eji.201646632 |
0.349 |
|
| 2017 |
Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA, Becker-Hapak M, Schappe T, Abdel-Latif S, Ireland AR, Jaishankar D, King JA, Vij R, ... ... Fehniger TA, et al. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. The Journal of Clinical Investigation. PMID 28972539 DOI: 10.1172/Jci90387 |
0.528 |
|
| 2017 |
Fehniger TA. CD70 turns on NK cells to attack lymphoma. Blood. 130: 238-239. PMID 28729334 DOI: 10.1182/Blood-2017-06-786244 |
0.403 |
|
| 2017 |
How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Romee R. T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide results in outcomes similar to traditionally matched donors in active disease acute myeloid leukemia. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 28087457 DOI: 10.1016/J.Bbmt.2017.01.068 |
0.354 |
|
| 2017 |
Huselton E, Slade M, DiPersio JF, Westervelt P, Vij R, Uy GL, Fehniger TA, Abboud CN, Gao F, Schroeder MA, Romee R. Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation. PMID 28067881 DOI: 10.1038/Bmt.2016.354 |
0.374 |
|
| 2017 |
Romee R, Cooley S, Berrien-Elliott M, Westervelt P, Verneris MR, Wagner JE, Weisdorf DJ, Blazar B, DiPersio JF, Cashen AF, Jeng EK, Rock A, Wong HC, Fehniger TA, Miller JS. First-in-Human Clinical Trial of the IL-15 Super-Agonist Complex ALT-803 for Patients Relapsed after Allogeneic Hematopoietic Cell Transplantation Blood. 130: 274-274. DOI: 10.1182/Blood.V130.Suppl_1.274.274 |
0.506 |
|
| 2017 |
Berrien-Elliott M, Romee R, Wagner JA, Becker-Hapak M, Neal C, Schappe T, McCullen M, Cooper M, Fehniger TA. NKG2A Represents an Important Immune Checkpoint for Human Cytokine-Induced Memory-like NK Cells in Patients with AML Blood. 130: 167-167. DOI: 10.1182/Blood.V130.Suppl_1.167.167 |
0.497 |
|
| 2017 |
Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Uy GL, Abboud C, Vij R, Schroeder MA, Fehniger T, Romee R. Donor-Lymphocyte Infusion Following Haploidentical Hematopoietic Cell Transplantation with Peripheral Blood Stem Cell Grafts and PTCy Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2017.01.024 |
0.371 |
|
| 2017 |
How J, Slade M, Vu K, DiPersio JF, Westervelt P, Uy GL, Abboud C, Vij R, Schroeder MA, Fehniger T, Romee R. T-Cell Replete Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Results in Outcomes Similar to Those of Traditionally Matched Donors in Active Acute Myeloid Leukemia Biology of Blood and Marrow Transplantation. 23. DOI: 10.1016/J.Bbmt.2016.12.184 |
0.368 |
|
| 2016 |
Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Trani L, Fronick CC, Fulton RS, Kreisel F, Cashen AF, Carson KR, Berrien-Elliott MM, Bartlett NL, Griffith M, Griffith OL, ... Fehniger TA, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. PMID 28064239 DOI: 10.1182/Blood-2016-07-729954 |
0.307 |
|
| 2016 |
Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, ... ... Fehniger TA, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. The New England Journal of Medicine. 375: 2023-2036. PMID 27959731 DOI: 10.1056/Nejmoa1605949 |
0.311 |
|
| 2016 |
Wagner JA, Berrien-Elliott MM, Rosario M, Leong JW, Jewell BA, Schappe T, Abdel-Latif S, Fehniger TA. Cytokine-Induced Memory-Like Differentiation Enhances Unlicensed NK Cell Anti-Leukemia and FcγRIIIa-Triggered Responses. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 27894857 DOI: 10.1016/J.Bbmt.2016.11.018 |
0.49 |
|
| 2016 |
Fehniger TA, Cooper MA. Harnessing NK Cell Memory for Cancer Immunotherapy. Trends in Immunology. PMID 27773685 DOI: 10.1016/J.It.2016.09.005 |
0.482 |
|
| 2016 |
Cantoni C, Cignarella F, Ghezzi L, Mikesell B, Bollman B, Berrien-Elliott MM, Ireland AR, Fehniger TA, Wu GF, Piccio L. Mir-223 regulates the number and function of myeloid-derived suppressor cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Acta Neuropathologica. PMID 27704281 DOI: 10.1007/S00401-016-1621-6 |
0.307 |
|
| 2016 |
Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, Neal CC, Yu L, Oh ST, Lee YS, Mulder A, ... ... Fehniger TA, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Science Translational Medicine. 8: 357ra123. PMID 27655849 DOI: 10.1126/Scitranslmed.Aaf2341 |
0.49 |
|
| 2016 |
Goldsmith SR, Slade M, DiPersio JF, Westervelt P, Lawrence SJ, Uy GL, Abboud CN, Vij R, Schroeder MA, Fehniger TA, Dubberke ER, Trinkaus K, Romee R. Cytomegalovirus viremia, disease, and impact on relapse in T-cell replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. Haematologica. PMID 27443287 DOI: 10.3324/Haematol.2016.149880 |
0.369 |
|
| 2016 |
Abboud R, Keller J, Slade M, DiPersio JF, Westervelt P, Rettig MP, Meier S, Fehniger TA, Abboud CN, Uy GL, Vij R, Trinkaus KM, Schroeder MA, Romee R. Severe Cytokine Release Syndrome Following T-Cell Replete Peripheral Blood Haploidentical Donor Transplant is Associated with Poor Survival and Anti-IL-6 Therapy is Safe and Well Tolerated. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 27318038 DOI: 10.1016/J.Bbmt.2016.06.010 |
0.38 |
|
| 2016 |
Rashidi A, DiPersio JF, Westervelt P, Vij R, Schroeder MA, Cashen AF, Fehniger TA, Romee R. Comparison of outcomes following peripheral blood haploidentical vs. matched unrelated donor allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia: a retrospective single-center review. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. PMID 27223108 DOI: 10.1016/J.Bbmt.2016.05.010 |
0.335 |
|
| 2016 |
Wagner JA, Fehniger TA. Human Adaptive Natural Killer Cells: Beyond NKG2C. Trends in Immunology. PMID 27179621 DOI: 10.1016/J.It.2016.05.001 |
0.455 |
|
| 2016 |
Rashidi A, DiPersio JF, Westervelt P, Abboud CN, Schroeder MA, Pusic I, Cashen AF, Fehniger TA, Romee R. HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation. PMID 27159170 DOI: 10.1038/Bmt.2016.117 |
0.333 |
|
| 2016 |
Leong JW, Wagner JA, Ireland AR, Fehniger TA. Transcriptional and post-transcriptional regulation of NK cell development and function. Clinical Immunology (Orlando, Fla.). PMID 26948928 DOI: 10.1016/J.Clim.2016.03.003 |
0.443 |
|
| 2016 |
Wagner JA, Romee R, Rosario M, Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA, Schappe T, Abdel-Latif S, Ireland AR, Jaishankar D, King JA, Vij R, Fehniger TA. Human CD56bright NK Cells Acquire Potent Anti-Leukemia Functionality Following IL-15 Priming Blood. 128: 550-550. DOI: 10.1182/Blood.V128.22.550.550 |
0.525 |
|
| 2016 |
Slade M, Goldsmith SR, DiPersio JF, Westervelt P, Vij R, Fehniger TA, Schroeder MA, Romee R. The Use of CD34 + -Selected Stem Cell Boosts Following HLA-Haploidentical Hematopoietic Cell Transplantation Blood. 128: 4697-4697. DOI: 10.1182/Blood.V128.22.4697.4697 |
0.444 |
|
| 2016 |
Abboud R, Slade M, Ballard W, Keller J, DiPersio JF, Westervelt P, Abboud CN, Fehniger TA, Trinkaus K, Romee R. Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant Blood. 128: 3419-3419. DOI: 10.1182/Blood.V128.22.3419.3419 |
0.352 |
|
| 2016 |
Krysiak K, Gomez F, White BS, Matlock M, Miller CA, Fulton RS, Kreisel F, Cashen AF, Carson KR, Berrien-Elliott MM, Bartlett NL, Wilson RK, Mardis ER, Griffith M, Griffith OL, ... Fehniger TA, et al. Abstract LB-326: Identification of novel recurrent mutations in follicular lymphoma Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-326 |
0.315 |
|
| 2015 |
Rosario M, Liu B, Kong L, Collins L, Schneider SE, Chen X, Han KP, Jeng EK, Rhode PR, Leong JW, Schappe T, Jewell B, Keppel CR, Shah K, Hess B, ... ... Fehniger TA, et al. The IL-15-based ALT-803 complex enhances FcγRIIIa-triggered NK cell responses and in vivo clearance of B cell lymphomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26423796 DOI: 10.1158/1078-0432.Ccr-15-1419 |
0.457 |
|
| 2015 |
Berrien-Elliott MM, Romee R, Fehniger TA. Improving natural killer cell cancer immunotherapy. Current Opinion in Organ Transplantation. 20: 671-80. PMID 26414502 DOI: 10.1097/Mot.0000000000000243 |
0.499 |
|
| 2015 |
Wagner JA, Fehniger TA. Memory NK Cells Take Out the (Mitochondrial) Garbage. Immunity. 43: 218-20. PMID 26287678 DOI: 10.1016/J.Immuni.2015.08.009 |
0.353 |
|
| 2015 |
Sullivan RP, Leong JW, Schneider SE, Ireland AR, Berrien-Elliott MM, Singh A, Schappe T, Jewell BA, Sexl V, Fehniger TA. MicroRNA-15/16 Antagonizes Myb To Control NK Cell Maturation. Journal of Immunology (Baltimore, Md. : 1950). 195: 2806-17. PMID 26268657 DOI: 10.4049/Jimmunol.1500949 |
0.427 |
|
| 2015 |
Berrien-Elliott MM, Wagner JA, Fehniger TA. Human Cytokine-Induced Memory-Like Natural Killer Cells. Journal of Innate Immunity. PMID 25924651 DOI: 10.1159/000382019 |
0.487 |
|
| 2015 |
Vu K, Manjappa S, DiPersio JF, Gao F, Westervelt P, Vij R, Stockerl-Goldstein KE, Uy GL, Abboud CN, Schroeder MA, Fehniger TA, Cashen AF, Romee R. Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 1425-30. PMID 25840336 DOI: 10.1016/J.Bbmt.2015.03.022 |
0.344 |
|
| 2015 |
Leong JW, Schneider SE, Sullivan RP, Parikh BA, Anthony BA, Singh A, Jewell BA, Schappe T, Wagner JA, Link DC, Yokoyama WM, Fehniger TA. PTEN regulates natural killer cell trafficking in vivo. Proceedings of the National Academy of Sciences of the United States of America. 112: E700-9. PMID 25646418 DOI: 10.1073/Pnas.1413886112 |
0.485 |
|
| 2015 |
Carson KR, Riedell P, Lynch R, Nabhan C, Wildes TM, Liu W, Ganti A, Roop R, Sanfilippo KM, O'Brian K, Liu J, Bartlett NL, Cashen A, Wagner-Johnston N, Fehniger TA, et al. Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma. Journal of Geriatric Oncology. 6: 211-8. PMID 25614297 DOI: 10.1016/J.Jgo.2015.01.003 |
0.311 |
|
| 2015 |
Welch JS, Petti A, Miller CA, Link DC, Walter MJ, Fronick CC, Fulton RS, Wartman LD, Uy GL, Ghobadi A, Tomasson M, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein K, et al. Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients Blood. 126: 689-689. DOI: 10.1182/Blood.V126.23.689.689 |
0.329 |
|
| 2015 |
Ward JP, Thein J, Luo J, Wagner-Johnston ND, Cashen AF, Fehniger TA, Bartlett NL. A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Blood. 126: 3988-3988. DOI: 10.1182/Blood.V126.23.3988.3988 |
0.338 |
|
| 2015 |
Han Sy, Bhamidipati PK, Vu K, Dipersio JF, Gao F, Pusic I, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Stockerl-Goldstein K, Cashen AF, Fehniger TA, Romee R. Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation Blood. 126: 3144-3144. DOI: 10.1182/Blood.V126.23.3144.3144 |
0.312 |
|
| 2015 |
Abboud R, Keller J, Slade M, Rettig MP, Meier S, DiPersio JF, Fehniger TA, Trinkaus K, Uy GL, Westervelt P, Vij R, Abboud CN, Vu K, Bhamidipati PK, Romee R. T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy Blood. 126: 3106-3106. DOI: 10.1182/Blood.V126.23.3106.3106 |
0.377 |
|
| 2015 |
Miller JS, Cooley S, Holtan S, Arora M, Ustun C, Jeng E, Wong HC, Verneris MR, Wagner JE, Weisdorf DJ, Blazar BR, Fehniger TA, Romee R. 'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15Rα-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy Blood. 126: 1957-1957. DOI: 10.1182/Blood.V126.23.1957.1957 |
0.439 |
|
| 2015 |
Hess BT, Gao F, DiPersio JF, Westervelt P, Vij R, Uy GL, Stockerl-Goldstein K, Abboud CN, Schroeder MA, Pusic I, Ghobadi A, Cashen AF, Fehniger TA, Jacoby MA, Romee R. Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes Blood. 126: 1950-1950. DOI: 10.1182/Blood.V126.23.1950.1950 |
0.347 |
|
| 2015 |
Romee R, Maximillian R, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Schneider SE, Willey S, Fehniger TA. Human Cytokine-Induced Memory-like NK Cells Exhibit in Vivo Anti-Leukemia Activity in Xenografted NSG Mice and in Patients with Acute Myeloid Leukemia (AML) Blood. 126: 101-101. DOI: 10.1182/Blood.V126.23.101.101 |
0.526 |
|
| 2015 |
Fehniger TA. Natural killer cells: Basic biology and immunotherapy potential Aacr Education Book. 2015: 85-88. DOI: 10.1158/AACR.EDB-15-8030 |
0.319 |
|
| 2014 |
Leong JW, Sullivan RP, Fehniger TA. microRNA management of NK-cell developmental and functional programs. European Journal of Immunology. 44: 2862-8. PMID 25142111 DOI: 10.1002/Eji.201444798 |
0.381 |
|
| 2014 |
Romee R, Leong JW, Fehniger TA. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica. 2014: 205796. PMID 25054077 DOI: 10.1155/2014/205796 |
0.382 |
|
| 2014 |
Bhamidipati PK, DiPersio JF, Stokerl-Goldstein K, Rashidi A, Gao F, Uy GL, Westervelt P, Vij R, Schroeder MA, Abboud CN, Keller JW, Fehniger TA, Romee R. Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. Bone Marrow Transplantation. 49: 1124-6. PMID 24842528 DOI: 10.1038/Bmt.2014.108 |
0.322 |
|
| 2014 |
Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, Fehniger TA. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 463-73. PMID 24434782 DOI: 10.1016/J.Bbmt.2014.01.006 |
0.398 |
|
| 2014 |
Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, et al. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 20: 46-52. PMID 24120526 DOI: 10.1016/J.Bbmt.2013.10.003 |
0.35 |
|
| 2014 |
Rosario M, Liu B, Kong L, Schneider SE, Jeng EK, Rhode PR, Wong HC, Fehniger TA. The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK cell ADCC and in vivo clearance of B cell lymphomas Journal For Immunotherapy of Cancer. 2: 168. DOI: 10.1186/2051-1426-2-S3-P168 |
0.508 |
|
| 2014 |
Rosario M, Liu B, Kong L, Schneider SE, Jeng EK, Rhode PR, Wong H, Fehniger TA. The IL-15 Superagonist ALT-803 Enhances NK Cell ADCC and in Vivo Clearance of B Cell Lymphomas Directed By an Anti-CD20 Monoclonal Antibody Blood. 124: 807-807. DOI: 10.1182/Blood.V124.21.807.807 |
0.491 |
|
| 2014 |
Fehniger TA, Stuart RK, Cooley SA, Miller JS, Curtsinger J, Hillman TM, Silver N, Szarek M, Lowdell MW, Gorelik L, Rowinsky E. Preliminary Results of a Phase 1/2 Clinical Trial of Cndo-109-Activated Allogeneic Natural Killer Cells in High Risk Acute Myelogenous Leukemia Patients in First Complete Remission Blood. 124: 2320-2320. DOI: 10.1182/Blood.V124.21.2320.2320 |
0.538 |
|
| 2014 |
Rosario M, Romee R, Schneider SE, Leong JW, Sullivan RP, Fehniger TA. Human Cytokine-Induced Memory-like (CIML) NK Cells Are Active Against Myeloid Leukemia in Vitro and in Vivo Blood. 124: 1117-1117. DOI: 10.1182/Blood.V124.21.1117.1117 |
0.537 |
|
| 2013 |
Sullivan RP, Fogel LA, Leong JW, Schneider SE, Wong R, Romee R, Thai TH, Sexl V, Matkovich SJ, Dorn GW, French AR, Fehniger TA. MicroRNA-155 tunes both the threshold and extent of NK cell activation via targeting of multiple signaling pathways. Journal of Immunology (Baltimore, Md. : 1950). 191: 5904-13. PMID 24227772 DOI: 10.4049/Jimmunol.1301950 |
0.403 |
|
| 2013 |
Fehniger TA. Extracellular microRNAs turn on NK cells via TLR1. Blood. 121: 4612-3. PMID 23744491 DOI: 10.1182/Blood-2013-04-497594 |
0.316 |
|
| 2013 |
Fehniger TA. "AbroGATAed" human NK cell development. Blood. 121: 2579-80. PMID 23557967 DOI: 10.1182/Blood-2013-02-483362 |
0.385 |
|
| 2013 |
Sullivan RP, Leong JW, Fehniger TA. MicroRNA regulation of natural killer cells. Frontiers in Immunology. 4: 44. PMID 23450173 DOI: 10.3389/Fimmu.2013.00044 |
0.374 |
|
| 2013 |
Romee R, Leong JW, Schneider SE, Sullivan RP, Cooper M, Fehniger TA. Human Cytokine-Induced Memory-Like (CIML) NK Cells Exhibit Potent Anti-Leukemia Cytotoxicity and Maintain Memory-Like Functionality After Adoptive Transfer Into Immunodeficient NOD-SCID-Gc-/- (NSG) Mice Blood. 122: 4501-4501. DOI: 10.1182/Blood.V122.21.4501.4501 |
0.507 |
|
| 2013 |
Romee R, Leong JW, Schneider SE, Sullivan RP, Fehniger TA. IL-15 Primes a Highly Potent Anti-Leukemia Response By CD56bright NK Cells Blood. 122: 2283-2283. DOI: 10.1182/Blood.V122.21.2283.2283 |
0.466 |
|
| 2013 |
Sullivan RP, Leong JW, Schneider SE, Romee R, Sexl V, Dalla-Favera R, Fehniger TA. Mir-15/16 Antagonizes Myb To Control Natural Killer Cell Differentiation and Maturation Blood. 122: 17-17. DOI: 10.1182/Blood.V122.21.17.17 |
0.464 |
|
| 2012 |
Leong JW, Sullivan RP, Fehniger TA. Natural killer cell regulation by microRNAs in health and disease. Journal of Biomedicine & Biotechnology. 2012: 632329. PMID 23226942 DOI: 10.1155/2012/632329 |
0.463 |
|
| 2012 |
Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, Cooper MA, Fehniger TA. Cytokine activation induces human memory-like NK cells. Blood. 120: 4751-60. PMID 22983442 DOI: 10.1182/Blood-2012-04-419283 |
0.457 |
|
| 2012 |
Sullivan RP, Leong JW, Schneider SE, Keppel CR, Germino E, French AR, Fehniger TA. MicroRNA-deficient NK cells exhibit decreased survival but enhanced function. Journal of Immunology (Baltimore, Md. : 1950). 188: 3019-30. PMID 22379033 DOI: 10.4049/Jimmunol.1102294 |
0.424 |
|
| 2012 |
Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J. T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 18: 937-43. PMID 22155505 DOI: 10.1016/J.Bbmt.2011.11.024 |
0.392 |
|
| 2012 |
Romee R, Stephanie S, Leong JW, Chase JM, Keppel CR, Sullivan R, Cooper M, Fehniger TA. Cytokine Activation and CD16 Cross-Linking Leads to the Generation of Human Memory-Like NK Cells Blood. 120: 3291-3291. DOI: 10.1182/Blood.V120.21.3291.3291 |
0.448 |
|
| 2012 |
Chase JM, Leong JW, Romee R, Fehniger TA. Cytokine Activation Induces CD25 Expression and a Signaling-Competent High-Affinity IL-2 Receptor On CD56dim Human NK Cells. Blood. 120: 2159-2159. DOI: 10.1182/Blood.V120.21.2159.2159 |
0.425 |
|
| 2012 |
Christian B, Wei L, Sexton J, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston N, Bartlett NL, Blum KA. A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor, Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin’s Lymphoma (HL) Blood. 120: 1644-1644. DOI: 10.1182/Blood.V120.21.1644.1644 |
0.322 |
|
| 2012 |
Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Hurd DD, Blum KA, Goy A, Fenske TS, Cashen A, Wagner-Johnston ND, Carson KR, Bartlett NL. A Phase 2 Multicenter Study of Continuous Dose Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma Blood. 120: 1623-1623. DOI: 10.1182/Blood.V120.21.1623.1623 |
0.32 |
|
| 2011 |
Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, Fenske TS, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston ND, Carson KR, Bartlett NL. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 118: 5119-25. PMID 21937701 DOI: 10.1182/Blood.V114.22.3693.3693 |
0.339 |
|
| 2011 |
Leong JW, Fehniger TA. Human NK cells: SET to kill. Blood. 117: 2297-8. PMID 21350056 DOI: 10.1182/Blood-2011-01-327247 |
0.423 |
|
| 2011 |
Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Westervelt P, DiPersio JF, Vij R. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood. 117: 1828-33. PMID 21051557 DOI: 10.1182/Blood-2010-07-297143 |
0.309 |
|
| 2011 |
Sullivan RP, Leong JW, Schneider SE, Keppel CR, Germino E, French AR, Fehniger TA. MicroRNA-Deficient Murine NK Cells Exhibit Impaired Development and Survival but Enhanced IFN-γ Production In Vitro and In Vivo Blood. 118: 357-357. DOI: 10.1182/Blood.V118.21.357.357 |
0.445 |
|
| 2010 |
Fehniger TA, Wylie T, Germino E, Leong JW, Magrini VJ, Koul S, Keppel CR, Schneider SE, Koboldt DC, Sullivan RP, Heinz ME, Crosby SD, Nagarajan R, Ramsingh G, Link DC, et al. Next-generation sequencing identifies the natural killer cell microRNA transcriptome. Genome Research. 20: 1590-604. PMID 20935160 DOI: 10.1101/Gr.107995.110 |
0.363 |
|
| 2010 |
Martin MG, Welch JS, Uy GL, Fehniger TA, Kulkarni S, Duncavage EJ, Walter MJ. Limited engraftment of low-risk myelodysplastic syndrome cells in NOD/SCID gamma-C chain knockout mice. Leukemia. 24: 1662-4. PMID 20668474 DOI: 10.1038/Leu.2010.156 |
0.3 |
|
| 2010 |
White DW, Keppel CR, Schneider SE, Reese TA, Coder J, Payton JE, Ley TJ, Virgin HW, Fehniger TA. Latent herpesvirus infection arms NK cells. Blood. 115: 4377-83. PMID 20139098 DOI: 10.1182/Blood-2009-09-245464 |
0.452 |
|
| 2010 |
Cai SF, Cao X, Hassan A, Fehniger TA, Ley TJ. Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. Blood. 115: 1669-77. PMID 19965675 DOI: 10.1182/Blood-2009-07-233676 |
0.372 |
|
| 2010 |
Fehniger TA, Wylie T, Germino E, Leong JW, Magrini VJ, Koul S, Keppel CR, Schneider SE, Koboldt DC, Sullivan RP, Heinz ME, Crosby SD, Nagarajan R, Ramsingh G, Link DC, et al. The NK Cell MicroRNA Transcriptome Defined by Next-Generation Sequencing Identifies IL-15-Signaled Alterations In Mature MiR-223 Expression, and MiR-223 as a Potential Regulator of Murine Granzyme B Blood. 116: 104-104. DOI: 10.1182/Blood.V116.21.104.104 |
0.328 |
|
| 2009 |
Cai SF, Fehniger TA, Cao X, Mayer JC, Brune JD, French AR, Ley TJ. Differential expression of granzyme B and C in murine cytotoxic lymphocytes. Journal of Immunology (Baltimore, Md. : 1950). 182: 6287-97. PMID 19414782 DOI: 10.4049/Jimmunol.0804333 |
0.365 |
|
| 2009 |
Vij R, Nelson A, Uy GL, Abboud C, Westervelt P, Cashen AF, Keith S, Trinkhaus KM, DiPersio JF, Fehniger TA. A Phase II Study of High Dose Lenalidomide as Initial Therapy for Acute Myeloid Leukemia in Patients > 60 Years Old. Blood. 114: 842-842. DOI: 10.1182/Blood.V114.22.842.842 |
0.301 |
|
| 2009 |
White DW, Keppel CR, Schneider SE, Coder J, Reese TA, Payton JE, Ley TJ, Virgin HW, Fehniger TA. Latent Murine Herpesvirus-4 Infection Arms NK Cells. Blood. 114: 3678-3678. DOI: 10.1182/Blood.V114.22.3678.3678 |
0.465 |
|
| 2007 |
Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 27: 635-46. PMID 17919943 DOI: 10.1016/J.Immuni.2007.08.014 |
0.41 |
|
| 2007 |
French AR, Kim S, Fehniger TA, Pratt JR, Yang L, Song YJ, Caligiuri MA, Yokoyama WM. Chronic lymphocytosis of functionally immature natural killer cells. The Journal of Allergy and Clinical Immunology. 120: 924-31. PMID 17604094 DOI: 10.1016/J.Jaci.2007.05.022 |
0.458 |
|
| 2007 |
Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, Ley TJ. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity. 26: 798-811. PMID 17540585 DOI: 10.1016/J.Immuni.2007.04.010 |
0.47 |
|
| 2007 |
Fehniger TA, Nelson A, Trinkaus K, Abboud CN, Cashen AF, DiPersio JF, Graubert TA, Ley TJ, Tomasson MH, Uy GL, Walter MJ, Westervelt P, Vij R. Phase II Study of High Dose Lenalidomide as Initial Treatment for Older Acute Myeloid Leukemia Patients: Early Results Show a Significant Reduction of Bone Marrow Blasts after 14 Days of Therapy. Blood. 110: 916-916. DOI: 10.1182/Blood.V110.11.916.916 |
0.308 |
|
| 2007 |
Cai SF, Fehniger TA, Dai X, Cao X, Ley TJ. Differential Regulation of Granzyme B and C Expression in Murine Cytotoxic T and NK Cells. Blood. 110: 2291-2291. DOI: 10.1182/Blood.V110.11.2291.2291 |
0.414 |
|
| 2007 |
Fehniger TA. Orphan granzyme turned lethal weapon Blood. 110: 475-476. DOI: 10.1182/Blood-2007-04-085225 |
0.444 |
|
| 2006 |
Bredemeyer AJ, Carrigan PE, Fehniger TA, Smith DF, Ley TJ. Hop cleavage and function in granzyme B-induced apoptosis. The Journal of Biological Chemistry. 281: 37130-41. PMID 17005566 DOI: 10.1074/Jbc.M607969200 |
0.324 |
|
| 2006 |
Fehniger TA, Cai SF, Cao X, Bredemeyer AJ, Presti RM, French AR, Ley TJ. Murine NK Cells Require Activation-Dependent Expression of Granzyme B and Perforin To Become Potent Cytotoxic Effectors. Blood. 108: 920-920. DOI: 10.1182/Blood.V108.11.920.920 |
0.445 |
|
| 2006 |
Cao X, Cai SF, Fehniger TA, Song J, Piwnica-Worms D, Ley TJ. Granzyme B Is Important for Treg-Mediated Suppression of NK-Dependent Tumor Clearance In Vivo. Blood. 108: 133-133. DOI: 10.1182/Blood.V108.11.133.133 |
0.397 |
|
| 2004 |
Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA. NK cell and DC interactions. Trends in Immunology. 25: 47-52. PMID 14698284 DOI: 10.1016/J.It.2003.10.012 |
0.408 |
|
| 2003 |
Farag SS, VanDeusen JB, Fehniger TA, Caligiuri MA. Biology and clinical impact of human natural killer cells. International Journal of Hematology. 78: 7-17. PMID 12894845 DOI: 10.1007/Bf02983234 |
0.509 |
|
| 2003 |
Farag SS, Fehniger TA, Becknell B, Blaser BW, Caligiuri MA. New directions in natural killer cell-based immunotherapy of human cancer. Expert Opinion On Biological Therapy. 3: 237-50. PMID 12662139 DOI: 10.1517/14712598.3.2.237 |
0.482 |
|
| 2003 |
Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, Caligiuri MA. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 101: 3052-7. PMID 12480696 DOI: 10.1182/Blood-2002-09-2876 |
0.453 |
|
| 2003 |
Farag SS, Fehniger T, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cells: biology and application in stem-cell transplantation. Cytotherapy. 4: 445-6. PMID 12473220 DOI: 10.1080/146532402320776134 |
0.394 |
|
| 2002 |
Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood. 100: 3633-8. PMID 12393617 DOI: 10.1182/Blood-2001-12-0293 |
0.441 |
|
| 2002 |
Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 100: 1935-47. PMID 12200350 DOI: 10.1182/Blood-2002-02-0350 |
0.454 |
|
| 2002 |
Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine & Growth Factor Reviews. 13: 169-83. PMID 11900992 DOI: 10.1016/S1359-6101(01)00021-1 |
0.327 |
|
| 2002 |
Fehniger TA, Caligiuri MA. Ontogeny and expansion of human natural killer cells: clinical implications. International Reviews of Immunology. 20: 503-34. PMID 11878513 DOI: 10.3109/08830180109054417 |
0.494 |
|
| 2001 |
Comella K, Nakamura M, Melnik K, Chosy J, Zborowski M, Cooper MA, Fehniger TA, Caligiuri MA, Chalmers JJ. Effects of antibody concentration on the separation of human natural killer cells in a commercial immunomagnetic separation system. Cytometry. 45: 285-93. PMID 11746098 DOI: 10.1002/1097-0320(20011201)45:4<285::Aid-Cyto10018>3.0.Co;2-W |
0.381 |
|
| 2001 |
Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends in Immunology. 22: 633-40. PMID 11698225 DOI: 10.1016/S1471-4906(01)02060-9 |
0.446 |
|
| 2001 |
Fehniger TA, Suzuki K, VanDeusen JB, Cooper MA, Freud AG, Caligiuri MA. Fatal leukemia in interleukin-15 transgenic mice. Blood Cells, Molecules & Diseases. 27: 223-30. PMID 11358383 DOI: 10.1006/Bcmd.2001.0379 |
0.347 |
|
| 2001 |
Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 97: 3146-51. PMID 11342442 DOI: 10.1182/Blood.V97.10.3146 |
0.443 |
|
| 2001 |
Cooper MA, Fehniger TA, Ponnappan A, Mehta V, Wewers MD, Caligiuri MA. Interleukin-1beta costimulates interferon-gamma production by human natural killer cells. European Journal of Immunology. 31: 792-801. PMID 11241284 DOI: 10.1002/1521-4141(200103)31:3<792::Aid-Immu792>3.0.Co;2-U |
0.435 |
|
| 2001 |
Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, Caligiuri MA. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. The Journal of Experimental Medicine. 193: 219-31. PMID 11208862 DOI: 10.1084/Jem.193.2.219 |
0.398 |
|
| 2000 |
Fehniger TA, Bluman EM, Porter MM, Mrózek E, Cooper MA, VanDeusen JB, Frankel SR, Stock W, Caligiuri MA. Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. The Journal of Clinical Investigation. 106: 117-24. PMID 10880055 DOI: 10.1172/Jci6218 |
0.496 |
|
| 2000 |
Fehniger TA, Yu H, Cooper MA, Suzuki K, Shah MH, Caligiuri MA. Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. Journal of Immunology (Baltimore, Md. : 1950). 164: 1643-7. PMID 10657604 DOI: 10.4049/Jimmunol.164.4.1643 |
0.324 |
|
| 1999 |
Fehniger TA, Carson WE, Caligiuri MA. Costimulation of human natural killer cells is required for interferon gamma production. Transplantation Proceedings. 31: 1476-8. PMID 10330974 DOI: 10.1016/S0041-1345(99)00011-1 |
0.445 |
|
| 1998 |
Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunology, Immunotherapy : Cii. 46: 318-26. PMID 9756416 DOI: 10.1007/S002620050493 |
0.407 |
|
| 1998 |
Khatri VP, Fehniger TA, Baiocchi RA, Yu F, Shah MH, Schiller DS, Gould M, Gazzinelli RT, Bernstein ZP, Caligiuri MA. Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. The Journal of Clinical Investigation. 101: 1373-8. PMID 9502779 DOI: 10.1172/Jci2038 |
0.373 |
|
| 1998 |
Yu H, Fehniger TA, Fuchshuber P, Thiel KS, Vivier E, Carson WE, Caligiuri MA. Flt3 Ligand Promotes the Generation of a Distinct CD34+Human Natural Killer Cell Progenitor That Responds to Interleukin-15 Blood. 92: 3647-3657. DOI: 10.1182/Blood.V92.10.3647.422K43_3647_3657 |
0.466 |
|
| 1998 |
Yu H, Fehniger TA, Fuchshuber P, Thiel KS, Vivier E, Carson WE, Caligiuri MA. Flt3 Ligand Promotes the Generation of a Distinct CD34+Human Natural Killer Cell Progenitor That Responds to Interleukin-15 Blood. 92: 3647-3657. DOI: 10.1182/blood.v92.10.3647 |
0.365 |
|
| 1997 |
Carson WE, Fehniger TA, Haldar S, Eckhert K, Lindemann MJ, Lai CF, Croce CM, Baumann H, Caligiuri MA. A potential role for interleukin-15 in the regulation of human natural killer cell survival. The Journal of Clinical Investigation. 99: 937-43. PMID 9062351 DOI: 10.1172/Jci119258 |
0.388 |
|
| 1997 |
Carson WE, Fehniger TA, Caligiuri MA. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. European Journal of Immunology. 27: 354-60. PMID 9045904 DOI: 10.1002/Eji.1830270203 |
0.464 |
|
| 1997 |
Fehniger TA, Carson WE, Mrózek E, Caligiuri MA. Stem Cell Factor Enhances Interleukin-2–Mediated Expansion of Murine Natural Killer Cells In Vivo Blood. 90: 3647-3653. DOI: 10.1182/Blood.V90.9.3647 |
0.459 |
|
| Show low-probability matches. |